It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Clonal hematopoiesis of indeterminate potential (CHIP) is linked to diverse aging-related diseases, including hematologic malignancy and atherosclerotic cardiovascular disease (ASCVD). While CHIP is common among older adults, the underlying factors driving its development are largely unknown. To address this, we performed whole-exome sequencing on 8,374 blood DNA samples collected from 4,187 Atherosclerosis Risk in Communities Study (ARIC) participants over a median follow-up of 21 years. During this period, 735 participants developed incident CHIP. Splicing factor genes (SF3B1, SRSF2, U2AF1, and ZRSR2) and TET2 CHIP grow significantly faster than DNMT3A non-R882 clones. We find that age at baseline and sex significantly influence the incidence of CHIP, while ASCVD and other traditional ASCVD risk factors do not exhibit such associations. Additionally, baseline synonymous passenger mutations are strongly associated with CHIP status and are predictive of new CHIP clone acquisition and clonal growth over extended follow-up, providing valuable insights into clonal dynamics of aging hematopoietic stem and progenitor cells. This study also reveals associations between germline genetic variants and incident CHIP. Our comprehensive longitudinal assessment yields insights into cell-intrinsic and -extrinsic factors contributing to the development and progression of CHIP clones in older adults.
Clonal hematopoiesis of indeterminate potential (CHIP) is linked to diverse aging-related diseases but the underlying factors driving its development are largely unknown. Here, longitudinal assessment of 4,187 participants over 21 years provides insights into cell-intrinsic and -extrinsic factors contributing to the development and progression of CHIP clones in older adults.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 Broad Institute of MIT and Harvard, Program in Medical and Population Genetics, Cardiovascular Disease Initiative, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623); Massachusetts General Hospital, Cardiovascular Research Center, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)
2 Baylor College of Medicine, Department of Medicine, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X); Baylor College of Medicine, Center for Translational Research on Inflammatory Diseases, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X)
3 Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623); Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); University of Gothenburg, Institute of Biomedicine, SciLifeLab, Gothenburg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582)
4 The University of Texas Health Science Center at Houston, Department of Epidemiology, School of Public Health, Houston, USA (GRID:grid.267308.8) (ISNI:0000 0000 9206 2401)
5 Broad Institute of MIT and Harvard, Program in Medical and Population Genetics, Cardiovascular Disease Initiative, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623); Massachusetts General Hospital, Cardiovascular Research Center, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); KU Leuven, Department of Cardiovascular Sciences, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
6 Broad Institute of MIT and Harvard, Program in Medical and Population Genetics, Cardiovascular Disease Initiative, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623); Massachusetts General Hospital, Cardiovascular Research Center, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Harvard Medical School, Department of Medicine, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
7 Vanderbilt University Medical Center, Division of Genetic Medicine, Department of Medicine, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916)
8 Harvard Medical School, Department of Medicine, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Brigham and Women’s Hospital, Division of Cardiovascular Medicine, Department of Medicine, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294)
9 Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623); Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Howard Hughes Medical Institute, Boston, USA (GRID:grid.413575.1) (ISNI:0000 0001 2167 1581)
10 Baylor College of Medicine, Department of Medicine, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X)